Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class ...(dby the reduction of NT-proBNP plasma co...),Health

Date:6/20/2008

d by the reduction of NT-proBNP plasma concentration in the bosentan-treated group compared to the increase in the placebo-treated patients. It is generally considered that a decrease in plasma concentration of NT-proBNP following targeted PAH therapy is a predictive factor for patient outcome.

An open-label extension of EARLY is ongoing to establish the impact of early intervention on long-term patient outcome.

Notes to editor

About Pulmonary Arterial Hypertension (PAH)

PAH is a syndrome characterized by a progressive increase in pulmonary vascular resistance (PVR) leading to right ventricular failure and premature death.(4) If untreated, PAH carries a very poor prognosis with a median survival of 2.8 years after diagnosis.(5)

There are four WHO functional classes for PAH with class I being the least severe and class IV being the most advanced. These reflect the impact on a patient's life in terms of symptoms and physical activity. Class II patients are defined as patients with pulmonary hypertension resulting in mild limitation of physical activity, they are comfortable at rest and ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.(6)

The pathogenesis of PAH involves the increased production of vasoactive compounds, such as endothelin. Endothelin is produced by the endothelial cells and is essential for maintenance of normal vascular tone and function. Tracleer(R) was the first in a new class of treatments for PAH known as endothelin receptor antagonists. Tracleer(R) is a dual antagonist as it blocks both ETA and ETB receptors preventing the deleterious effects of endothelin.

Online information on PAH is available at http://www.pah-info.com. PAH-info.com is part of an international PAH awareness campaign supported by Actelion Pharmaceuticals and has been created to provide information to healthcare professionals and patients. '/>"/>

SOURCE Actelion Ltd Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
2. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
9. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
10. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
11. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol